NOMO-1

Description

NOMO-1 is a human leukemia cell line established from the peripheral blood of a female patient with acute monocytic leukemia (AML), FAB M5a. These cells exhibit a promonocytic characteristics and can differentiate into macrophage-like cells by 12-o-tetradecanoyl phorbol-13-acetate (TPA) treatment. The cells show increased levels of fibronectin and the secretion of Interleukin-1 (IL-1) α and IL-1 β after TPA stimulation. TPA also induces the secretion of tissue factors from NOMO-1, and this secretion can be inhibited by warfarin. Additionally, plasminogen activator (PA) activity increases during a 17-day culture period. NOMO-1 cells are cultured in RPMI-1640 medium with 10% FBS at 37°C with 5% CO2, and they are cryopreserved at liquid nitrogen temperatures. This cell line is valuable for studying the differentiation and maturation of monocytes, especially in relation to acute monocytic leukemia and macrophage-like differentiation.

Application

• NOMO-1 is a key model for studying the differentiation and maturation of monocytes and for identifying AML-specific antigens for therapeutic targeting. It is used in in drug development and investigating potential signaling pathways. It expresses granulocyte colony-stimulating factor (G-CSF) and responds to exogenous G-CSF. In the NOMO-1 model, it exogenous G-CSF enhances sensitivity to DNA topoisomerase II-targeting drugs and upregulates the expression of transferrin receptor (TfR). Additionally, NOMO-1 serves as a valuable model for studying drug resistance, having demonstrated resistant to pinometostat (EPZ-5676), a selective inhibitor of DOT1L.